Does ibogaine work for alcohol addiction?

Yes, in specific populations and with appropriate preparation. Ibogaine restores GDNF in the mesolimbic pathway — a neuroprotective protein depleted by chronic alcohol use — and resets opioid receptor physiology that sustains alcohol craving. Published research documents significant reductions in craving and alcohol use following single-session ibogaine treatment. The neuroplastic window created by ibogaine and sustained by noribogaine for weeks afterward is the period in which new patterns must be established through structured integration. Ibogaine is a neurological reset, not a cure. Returning to an unchanged environment without integration support produces relapse.

What are the alcohol-specific contraindications for ibogaine?

The most important alcohol-specific contraindication is liver disease. Ibogaine is hepatically metabolised, and alcohol damages the liver — AST and ALT levels must be within acceptable ranges before ceremony can proceed. Active alcohol withdrawal is also a contraindication — ibogaine ceremony is not the appropriate context to manage withdrawal, which can be fatal if severe. A medically supervised cessation period of 7–14 days is required before ceremony. SSRIs, which are commonly prescribed alongside AUD diagnoses, are absolute contraindications and require a completed supervised taper before any ceremony date is confirmed.

How long must I be alcohol-free before ibogaine ceremony?

A medically supervised cessation period of 7–14 days is standard. This timeline is not arbitrary — alcohol withdrawal in dependent individuals carries real risk, including seizures and in severe cases death. Stopping abruptly without medical supervision is not safe and is not what this preparation period involves. The cessation must be planned in advance with a physician who can monitor withdrawal and manage it if complications arise. Arriving at ceremony still drinking, or having stopped without supervision, disqualifies you from proceeding.

Is ibogaine for alcohol addiction covered by insurance?

No. Ibogaine treatment is not covered by any Canadian provincial health plan or US insurance because it is not approved for medical use in either country, though it is unscheduled in Canada. The full cost at Transcend in Vancouver ranges from $2,000–$5,000 CAD, which includes the on-site physician, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session — is separate. No deposit is required before candidacy is established through medical screening.

How does ibogaine compare to naltrexone for alcohol use disorder?

They act on different receptor systems and serve different stages of recovery. Naltrexone is an opioid antagonist taken daily, reducing the reward signal from alcohol without altering the underlying neurological pattern. It requires ongoing use and is most effective when combined with structured counselling. Ibogaine produces a single-session neurological reset — restoring GDNF, resetting opioid receptor sensitivity, and interrupting the craving circuit — without requiring ongoing dosing. Long-term outcomes for ibogaine appear to depend substantially on the integration period that follows, not just the ceremony. Neither is universally appropriate; candidacy for ibogaine is determined by cardiac and hepatic health, not by motivation alone.

Will ibogaine make me physically ill if I have been drinking heavily?

Ibogaine cannot be administered safely to someone in active alcohol use or acute withdrawal. The 7–14 day supervised cessation period is a prerequisite, not a recommendation. The medical screening — which includes liver function tests, a 12-lead EKG, and a full blood panel — must be completed before any ceremony date is set. People who have been drinking heavily for years often have elevated liver enzymes, and if these are significantly elevated, ceremony cannot proceed until they normalise. This may require more time and in some cases indicates that ibogaine is not appropriate at all.

How important is integration after ibogaine for alcohol addiction specifically?

More important than for most other presentations. Alcohol cues are embedded in restaurants, workplaces, family gatherings, and social situations that are difficult or impossible to avoid entirely. The neuroplastic window created by ibogaine — sustained by noribogaine for weeks to months — is when new patterns must be established before the old cues are repeatedly encountered again. Integration coaching at Transcend is $150–$300 CAD per session and is available remotely. Planning integration before the ceremony, not as an afterthought, is what separates outcomes that hold from outcomes that don't.

Who should not pursue ibogaine treatment for alcohol addiction?

Absolute contraindications include: significant liver disease (cirrhosis, hepatitis with active inflammation, or AST/ALT elevations above threshold); QT prolongation on EKG or significant cardiac arrhythmia; current SSRIs or SNRIs without a completed supervised taper; active psychosis or schizophrenia-spectrum disorder; pregnancy; methadone without a supervised transition protocol; and lithium. Someone in acute psychiatric crisis or active alcohol withdrawal is not an appropriate candidate at that time. Some of these — the SSRI taper, normalising liver enzymes — can be addressed over time. Others are permanent disqualifiers. The screening conversation is where that determination is made.

Ibogaine for Alcohol Addiction: What the Research Shows and Who It Is Not For

Ibogaine interrupts alcohol dependence through a mechanism no other treatment directly addresses: it restores GDNF — a neuroprotective protein depleted in alcohol-dependent brains — and resets the opioid receptor physiology that sustains craving. Published research shows significant reductions in alcohol use and craving following single-session ibogaine treatment. The contraindications specific to alcohol-dependent candidates differ from those in the general population, and one of them — liver disease — is common enough in this group that a meaningful number of people who most want this treatment cannot safely receive it.

Ibogaine addresses alcohol use disorder by restoring GDNF, resetting opioid receptor function, and interrupting the dopamine reward circuit that sustains alcohol craving. Published research documents significant craving reduction and reduced drinking following single-session treatment. A medically supervised cessation period, liver function panel, and 12-lead EKG are required before any ceremony date is confirmed.

How Ibogaine Addresses Alcohol Use Disorder

Alcohol dependence is not one problem. It involves disrupted dopamine signalling in the reward circuit, depleted GDNF (glial cell line-derived neurotrophic factor) in the mesolimbic pathway, sensitised opioid receptors that convert social drinking cues into compulsive urges, and — in many people — unprocessed trauma or chronic stress that alcohol has been managing. Ibogaine acts on several of these simultaneously.

The GDNF mechanism is the most pharmacologically specific. GDNF is a neuroprotective protein responsible for the survival and function of dopamine-producing neurons. Chronic heavy alcohol use depletes it. Ibogaine upregulates GDNF in the ventral tegmental area and striatum — the regions that govern reward and craving — at levels no currently approved treatment reaches. Animal studies have documented 90%+ reductions in voluntary alcohol consumption following a single ibogaine dose, persisting for weeks. This is the same GDNF pathway described in MAPS research summaries on ibogaine and chemical dependency.

The opioid receptor mechanism is also relevant for alcohol. Alcohol releases endogenous opioids — beta-endorphin primarily — and over time the opioid system adapts to expect this. Craving for alcohol is substantially an opioid craving displaced onto alcohol. Ibogaine resets opioid receptor sensitivity, removing the neurological substrate of that craving. This is why people who have been using alcohol as a management tool for pain or anxiety often report a distinct shift in the weeks following ibogaine ceremony: not that the pain or anxiety is gone, but that the pull toward alcohol to manage it is substantially reduced.

The third layer is the experiential one. Iboga ceremony brings into view the material a person has been managing around — the unresolved events, the patterns of avoidance, the emotional content alcohol has been suppressing rather than resolving. This is not comfortable. But it is, for many people, the work that cannot be done in any other way.

What the Research Shows

The published evidence for ibogaine and alcohol is smaller than for opioid dependence but consistent in direction. The 2023 Stanford study published in Nature Medicine documented 88% reductions in PTSD symptoms and 87% reductions in depression symptoms at one month in 30 special operations veterans. While the primary focus was PTSD, a significant portion of this population used alcohol as a coping mechanism — and the downstream reductions in those symptoms appear correlated with reduced alcohol use. The Texas clinical trials, receiving $50 million USD across UTMB, UTHealth Houston, Texas A&M, and Baylor, are designed to isolate alcohol use disorder among the conditions under study.

Earlier research from Lotsof, Mash, and colleagues documented single-session ibogaine producing significant reductions in alcohol craving and use in observational studies, with effects persisting for weeks to months. The methodological limitations of this work — no randomised controls, small samples, variable dosing — are genuine. But the direction is consistent across independent researchers across three decades, and the underlying mechanism (GDNF upregulation) now has enough preclinical documentation to anchor it.

Ibogaine is not a cure for alcohol addiction. It is a neurological reset — a window during which craving is reduced and new patterns become more possible. What happens in that window depends entirely on what the person does with it. Ibogaine ceremony followed by a return to the same environment, the same relationships, and the same unaddressed material that drove the drinking produces relapse. The window closes. The GDNF that was restored depletes again over months without the change in context and behaviour that integration is designed to support.

Dense old-growth rainforest, natural habitat of Tabernanthe iboga — Photo via Pexels

The Alcohol-Specific Preparation Requirement

The preparation requirements for alcohol-dependent candidates are more medically specific than for most other presentations. Two issues apply here that are not present at the same level in opioid-dependent candidates.

The first is liver function. Ibogaine is metabolised primarily in the liver. Alcohol causes liver damage — in many heavy drinkers, AST and ALT levels are elevated, and in some, more serious liver disease is present. A full blood panel including liver function tests is required before ceremony. If liver enzymes are significantly elevated, ibogaine cannot be safely administered. This is not a caution to be weighed — it is a hard medical limit. Providers who do not check liver function before ibogaine ceremony are operating unsafely.

The second is alcohol cessation. A medically supervised period of alcohol abstinence — typically 7–14 days, sometimes longer — is required before ibogaine ceremony. This is different from the opioid situation, where the goal is to arrive at a specific metabolite level. With alcohol, the risk is withdrawal. Alcohol withdrawal can produce seizures and, in severe cases, death. Unlike opioid withdrawal, which is agonising but not typically fatal, alcohol withdrawal in dependent individuals must be managed clinically. Showing up to ceremony still drinking, or having stopped abruptly without supervision, is not manageable within a ceremony context. The cessation period must be planned in advance with a physician.

The third preparation layer is medication review. SSRIs and SNRIs are absolute contraindications for ibogaine — and SSRIs are commonly prescribed for alcohol use disorder, anxiety, and depression. If you are on an SSRI, a supervised taper must be completed before any ceremony date is confirmed. This typically takes 2–4 weeks and must be managed with your prescribing physician.

The people who come to iboga ceremony with the strongest results are often the ones who spent years trying what was available first. Naltrexone. Acamprosate. AA. Therapy. Multiple detox admissions that held for months, then didn't. By the time they arrive, they are not naive about difficulty — they have evidence that the other approaches were not enough. That scepticism, earned the hard way, tends to produce people who are genuinely ready for what ibogaine shows them.

This is also the population for whom the preparation requirements are most worth taking seriously. A 7–14 day supervised cessation period and a liver panel are not bureaucratic obstacles. They are what makes the ceremony possible at all.

The Integration Window — and Why It Matters More for AUD

The neuroplastic window that ibogaine opens — sustained by noribogaine, ibogaine's active metabolite, which remains pharmacologically present for weeks to months — is the period in which lasting change becomes possible. For alcohol use disorder, this window matters more than it does for many other presentations. Here is why: alcohol is everywhere.

Opioid cues are geographically concentrated. Social settings, specific relationships, and the physical environment of use are things a person can, with effort, restructure. Alcohol cues are embedded in restaurants, workplaces, family gatherings, sporting events, and social situations that most people cannot avoid entirely. The integration period — the weeks after ceremony, before the neuroplastic window closes — is when the new patterns must be established, while the old cues are being encountered again.

This is not a reason to avoid ibogaine for alcohol addiction. It is a reason to plan integration before ceremony rather than after it. Integration coaching at Transcend is $150–$300 CAD per session and is available remotely. Packages of three or more sessions are available. The most common mistake is treating the ceremony as the finish line.

Who Is Not an Appropriate Candidate

Ibogaine for alcohol addiction is not for everyone. The following are absolute contraindications — not cautions to be weighed, but disqualifying conditions:

Significant liver disease. This includes cirrhosis, hepatitis with active inflammation, and AST/ALT elevations above a threshold established in the medical screening. Ibogaine is hepatically metabolised. Severe liver disease makes it unsafe to administer.
Current SSRIs or SNRIs without a completed taper. These medications are commonly prescribed alongside AUD diagnoses. They are absolute contraindications for ibogaine — the risk of serotonin syndrome is real and potentially fatal. No exception exists.
QT prolongation or significant cardiac arrhythmia. Ibogaine has cardiac effects that lengthen the QT interval. This is not a risk factor in people with normal cardiac function — it is a risk in people with pre-existing QT abnormalities. A 12-lead EKG is required. People with QT prolongation, recent myocardial infarction, or significant arrhythmia cannot proceed.
Active alcohol withdrawal or recent abrupt cessation without medical supervision. Arriving in withdrawal is a medical emergency, not a ceremony context. The cessation period must be planned and supervised in advance.
Active psychosis, schizophrenia spectrum disorder, or acute psychiatric crisis. The experience amplifies what is present. Entering iboga ceremony in a state of acute psychiatric instability does not produce stabilisation — it produces an amplified crisis.
Methadone or lithium. Both require specific protocols. Methadone requires a transition to a shorter-acting opioid before ceremony. Lithium is contraindicated.
Pregnancy. Absolute contraindication.

If you are primarily seeking a powerful experience, or hoping ibogaine will resolve alcohol use without engagement with the integration period that follows, this is not the right path at this time. The medicine does not accommodate avoidance.

Is This Right for You?

Ibogaine for alcohol addiction is appropriate for people who have done the work of conventional recovery and found it insufficient — not as an alternative to treatment, but as a neurological reset when treatment has stalled. It requires medical clearance, a supervised cessation period, and a serious engagement with the integration that follows.

If that describes your situation, the next step is to read the full FAQ and then submit an application. Every application receives a personal response within 2–3 business days. The screening conversation is where candidacy is established — not assumed. People with the conditions listed above are told directly and without softening. That is the most useful thing we can do for someone who is not an appropriate candidate.

The ceremony page covers the full programme — what medical screening involves, what 12–24 hours of active ceremony entails, and what the recovery period looks like. The Lotsof and Pearson 1995 paper in MAPS Bulletin provides additional historical research context for ibogaine and alcohol specifically. If you have questions not answered here, write to jake.nylund@gmail.com.